Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01941446
Recruitment Status : Completed
First Posted : September 13, 2013
Last Update Posted : September 13, 2013
Sponsor:
Information provided by (Responsible Party):
Tetraphase Pharmaceuticals, Inc.

Brief Summary:
This is a randomized, placebo- and positive-controlled (moxifloxacin), 3-period, 3-way crossover thorough QT study, which includes a Screening Period, Treatment Periods (1 through 3), and a Follow-up Visit. Subjects will be confined to the investigational site for 4 nights/3 days during Period 1 and for 3 nights/2 days during Periods 2 and 3. There will be a minimum of a 14 day washout between treatments.

Condition or disease Intervention/treatment Phase
Normal Healthy Subjects Drug: Eravacyline and Moxifloxacin Phase 1

Detailed Description:

Each of the following treatments will be evaluated on Day 1 of each period in a crossover fashion. The IV eravacycline (TP-434) and IV placebo will be double-blinded.

  • Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet;
  • Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet; and
  • Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet.

Subjects will be randomized to a treatment sequence according to a pre-generated treatment scheme. Subjects will receive a different treatment during each of the 3 periods.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo- and Positive Controlled, Three-Way, Crossover Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization in Healthy Male and Female Subjects: A Thorough QT/QTc Study
Study Start Date : March 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : July 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: pre-generated treatment scheme
Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes and one placebo oral tablet
Drug: Eravacyline and Moxifloxacin
Placebo Comparator: Pre-generated tratment scheme
Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one moxifloxacin 400 mg oral tablet
Drug: Eravacyline and Moxifloxacin
Placebo Comparator: Moxifloxacin
Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes and one placebo oral tablet



Primary Outcome Measures :
  1. Evaluate the effect of a therapeutic dose of an IV infusion of eravacycline (TP-434) on cardiac repolarization compared to placebo [ Time Frame: 11 weeks ]
    Calculating the differences between time-matched mean change from baseline of QTcI (ΔΔQTcI = ΔQTcI[TP-434]-ΔQTcI[placebo]) in healthy male and female subjects.


Secondary Outcome Measures :
  1. Evaluate the effect of eravacycline (TP-434) on cardiac repolarization [ Time Frame: 11 weeks ]
    • To evaluate the effect of eravacycline (TP-434) on cardiac repolarization compared with placebo by calculating the differences between the time-matched mean changes from baseline of QTcB (ΔΔQTcB) and QTcF (ΔΔQTcF) in healthy male and female subjects;
    • To evaluate the correlation between the differences in time-matched baseline-adjusted mean changes of QTc in eravacycline (TP-434) and placebo (ΔΔQTcI, ΔΔQTcB, and ΔΔQTcF) and plasma concentrations of eravacycline (TP-434), TP-498, and TP-6208;
    • To evaluate the correlation between QTcI, QTcB, and QTcF changes from baseline (ΔQTcI, ΔQTcB, and ΔQTcF) and plasma concentrations of eravacycline (TP-434), TP 498, and TP-6208; and
    • To evaluate assay sensitivity by measuring the effect of moxifloxacin on QTc compared to placebo (ΔΔQTcI).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male and female subjects of 18 to 55 years of age;
  2. Females must be surgically sterile (hysterectomy and/or bilateral oophorectomy), post-menopausal for 1 year (with follicle-stimulating hormone [FSH] in menopausal range), or agree to use 2 medically accepted, effective methods of birth control (e.g., hormonal contraception, including oral, implant/patch, or injection, or latex condom with spermicide, diaphragm with intravaginal spermicide, cervical cap with spermicide, or indwelling intrauterine device) from the time of signing informed consent until 2 weeks after the Follow-Up Visit. One of the birth control methods must be a barrier method;
  3. Male subjects with sexual partners of childbearing potential must agree to use 2 medically accepted, effective methods of birth control (e.g., hormonal contraception, including oral, implant/patch, or injection, or latex condom with spermicide, diaphragm with intravaginal spermicide, cervical cap with spermicide, or indwelling intrauterine device) for the duration of the study and for 90 days after the Follow-up Visit. Male subjects who have had a vasectomy >6 months prior to the first dose of study drug must agree to use 1 medically accepted barrier method for the duration of the study and for 90 days after the Follow-up Visit;
  4. Male subjects (including those who have had vasectomies >6 months prior to the first dose of study drug) whose partners are currently pregnant must agree to use a barrier method (without spermicide) for the duration of the study and for 2 weeks after the Follow-up Visit;
  5. Body mass index of 18 kg/m2 to 33 kg/m2, inclusive;
  6. Non-smokers must have quit smoking >3 months prior to the Screening Visit;
  7. Have negative alcohol and drug screens;
  8. Have a quantitative urine cotinine screen <3;
  9. Willing and able to be confined to the investigational site as required by the protocol; and
  10. Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines.

Exclusion Criteria:

  1. Evidence of clinically significant hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, or allergic disease (including multiple or clinically significant drug allergies), cancer, or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, interfere with the integrity of electrophysiologic data, or place the subject at an unacceptable risk as a participant in this study;
  2. A personal or family history of long QT syndrome, Torsades de pointes, or other complex ventricular arrhythmias or family history of sudden death;
  3. Mean QTcF interval >450 msec on screening ECG, performed in triplicate. The mean QTcF of these tracings will be used by the Investigator;
  4. Cardiac conduction abnormalities denoted by any of the following at the Screening Visit: evidence of second-degree (Mobitz type II) or third-degree atrioventricular block, evidence of ventricular pre-excitation, complete left bundle branch block, right bundle branch block, intraventricular conduction delay with QRS duration >120 msec, atrial fibrillation, or presence of cardiac pacemaker; PR interval >220 msec or <120 msec; heart rate <45 bpm or >90 bpm; other clinically-significant ECG abnormalities (measured as a mean value from triplicate ECGs);
  5. Use of hormone replacement therapy;
  6. Any major surgical procedure within 3 months prior to the first dose of study drug;
  7. Gastrointestinal disorders or surgical procedures that could interfere significantly with the absorption of orally administered drugs;
  8. Use of another investigational drug or device within 30 days prior to receiving eravacycline (TP-434), or within at least 5 half-lives of the previous investigational drug, whichever is longer;
  9. History of malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer);
  10. History or presence of hypertension (defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg). If the subject's blood pressure is outside of the acceptable range at the Screening Visit, the subject may be retested within 24 hours at the discretion of the Investigator;
  11. Known allergies to moxifloxacin, other quinolone or tetracycline antibiotics, or related compounds or a history of multiple adverse drug allergies of any origin;
  12. Inadequate venous access;
  13. Obvious clinical signs or symptoms of liver disease, acute or chronic active hepatitis, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 the upper limit of normal (ULN). An abnormal ALT or AST test may not be repeated;
  14. Total bilirubin >1.5 ULN with elevated direct bilirubin. An abnormal total or direct bilirubin test may not be repeated;
  15. Serum potassium, magnesium, or calcium levels that are outside of the laboratory's reference range;
  16. History of alcoholism or drug abuse within 2 years prior to dosing;
  17. Typical weekly alcohol consumption of 14 alcoholic drinks. One drink is defined as 1 glass of beer (approximately 10 oz to 12 oz) or 1 can (12 oz) of beer, 1 glass of wine (approximately 4 oz to 5 oz), or 1 glass of distilled spirits (hard liquor) containing 1 oz of the liquor (1 oz of liquid is approximately 30 mL);
  18. Alcohol consumption within 48 hours prior to dosing;
  19. Use of tobacco, nicotine, or nicotine-replacement products within the 3 months prior to the first dose of study drug through the last study visit;
  20. Unwillingness to refrain from caffeine and other xanthine-containing beverages, including coffee and tea, as well as grapefruit juice, Seville oranges, or chocolate within 24 hours prior to and after dosing;
  21. History of human immunodeficiency virus (HIV) or hepatitis C virus or a positive test at screening for HIV antibody, hepatitis C antibody, or hepatitis B surface antigen;
  22. Cumulative blood donation of >500 mL within 2 months prior to the Screening Visit;
  23. Use of any prescription or non-prescription medication, including vitamins or herbal medications, within 7 days, or 5 half-lives (if known), whichever is longer, prior to dosing in any of the 3 periods and within 24 hours after dosing in any period. The use of acetaminophen, naproxen, and ibuprofen is permitted except for within 24 hours prior to dosing;
  24. Use of any prescription or non-prescription medication that may cause QT prolongation within 14 days, or 5 half lives, whichever is longer, prior to dosing in Period 1 through 24 hours following dosing in Period 3;
  25. Any known exposure to prescription or non prescription medications or other substances, such as paint solvents or pesticides, known to induce or inhibit drug metabolizing enzymes or transport system enzymes, within 30 days or 5 half-lives, whichever is longer, prior to dosing in Period 1 through 24 hours following dosing in Period 3, with the exception of hormonal contraception;
  26. Unwillingness to abstain from strenuous exercise (e.g., heavy lifting, weight training, calisthenics, aerobics) for at least 48 hours prior to admission to the investigational site;
  27. Investigational site personnel directly affiliated with this study;
  28. Poor mental function or any other reason to expect subject difficulty in complying with the requirements of the study in the judgment of the Investigator; or
  29. Failure to comply with protocol requirements or whose further participation in the study would be unsuitable to the subject, as determined by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01941446


Sponsors and Collaborators
Tetraphase Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Patrick T. Horn, MD, PhD Tetraphase Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Tetraphase Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01941446     History of Changes
Other Study ID Numbers: TP-434-004
First Posted: September 13, 2013    Key Record Dates
Last Update Posted: September 13, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Layout table for MeSH terms
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs